Autonomic Function Tests

This LCD supplements but does not replace, modify or supersede existing Medicare applicable National Coverage Determinations (NCDs) or payment policy rules and regulations for autonomic function tests. Federal statute and subsequent Medicare regulations regarding provision and payment for medical services are lengthy. They are not repeated in this LCD. Neither Medicare payment policy rules nor this LCD replace, modify or supersede applicable state statutes regarding medical practice or other health practice professions acts, definitions and/or scopes of practice. All providers who report services for Medicare payment must fully understand and follow all existing laws, regulations and rules for Medicare payment for autonomic function tests and must properly submit only valid claims for them. Please review and understand them and apply the medical necessity provisions in the policy within the context of the manual rules. Relevant CMS manual instructions and policies may be found in the following Internet-Only Manuals (IOMs) published on the CMS Web site:

IOM Citations:

• CMS IOM Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 80 Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests
• CMS IOM Publication 100-03, Medicare National Coverage Determinations Manual, Chapter 1, Part 1 Section 70.2.1 Services Provided for the Diagnosis and Treatment of Diabetic Sensory Neuropathy with Loss of Protective Sensation (aka Diabetic Peripheral Neuropathy)
• CMS IOM Publication 100-08, Medicare Program Integrity Manual, Chapter 13, Section 13.5.4 Reasonable and Necessary Provision in an LCD

Social Security Act (Title XVIII) Standard References:

• Title XVIII of the Social Security Act, Section 1833(e) states that no payment shall be made to any provider for any claim that lacks the necessary information to process the claim.
• Title XVIII of the Social Security Act, Section 1862(a)(1)(A) states that no Medicare payment shall be made for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury.
• Title XVIII of the Social Security Act, Section 1862(a)(7). This section excludes routine physical examinations.

Notice: It is not appropriate to bill Medicare for services that are not covered (as described by this entire LCD) as if they are covered. When billing for non-covered services, use the appropriate modifier.

Compliance with the provisions in this policy may be monitored and addressed through post payment data analysis and subsequent medical review audits.

History/Background and/or General Information

The autonomic nervous system (ANS) regulates physiologic processes, such as blood pressure, heart rate, body temperature, digestion, metabolism, fluid and electrolyte balance, sweating, urination, defecation, sexual response, and other processes. Regulation occurs without conscious control, i.e., autonomously. The ANS has two major divisions: the sympathetic and parasympathetic systems. ANS testing measures alterations in the R-R interval of the electrocardiogram (ECG) in response to parasympathetic and sympathetic system stimulation. The aim of such testing is to correlate signs and symptoms of possible autonomic dysfunction with objective measurement in a way that is clinically useful. Many organs are controlled primarily by either the sympathetic or parasympathetic system, although they may receive input from both; occasionally, functions are reciprocal (e.g., sympathetic input increases heart rate; parasympathetic decreases it).

The sympathetic nervous system is catabolic and activates fight-or-flight responses. Thus, sympathetic output increases heart rate and contractility, bronchodilation, hepatic glycogenolysis and glucose release, BMR (basal metabolism rate), and muscular strength; it also causes sweaty palms. Less immediately-life-preserving functions (e.g., digestion, renal filtration) are decreased.

The parasympathetic nervous system is anabolic; it conserves and restores. Gastrointestinal secretions and motility (including evacuation) are stimulated, heart rate is slowed, and blood pressure decreases.

Disorders of the ANS can affect any system of the body; they can originate in the peripheral or central nervous system and may be primary or secondary to other disorders. Symptoms suggesting autonomic dysfunction include orthostatic hypotension, heat intolerance, nausea, constipation, urinary retention or incontinence, nocturia, impotence, and dry mucous membranes. If a patient has symptoms suggesting autonomic dysfunction, cardiovagal, adrenergic, and sudomotor tests are usually done to help determine severity and distribution of the dysfunction.

Drugs can have substantial effects on the results of ANS testing and are a common cause of falsely abnormal results. Patients should refrain from caffeine, nicotine, and alcohol at least 3 hours prior to testing. All medications with adrenergic and anticholinergic properties need to be discontinued at least 48 hours prior to the study. These would include but are not limited to the following drugs: chlorpromazine, thioridazine, the tricyclic and tetracyclic antidepressants, bupropion, mirtazapine, venlafaxine, clonidine, alpha-blockers, beta-blockers, calcium channel blockers, opiates, topical capsaicin, and diphenhydramine.

ANS testing can be grouped into three general categories:

• Cardiovagal innervation is a test that provides a standardized quantitative evaluation of vagal innervation to parasympathetic function of the heart. Responses are based on the interpretation of changes in continuous heart recordings in response to standardized maneuvers and include heart rate response to deep breathing, Valsalva ratio, and 30:15 ratio heart rate responses to standing. A tilt table is usually used for testing.
• Vasomotor adrenergic innervation evaluates adrenergic (sympathetic) innervation of the circulation and of the heart in autonomic failure. The following tests are included: beat-to-beat blood pressure and R-R interval response to Valsalva maneuver, sustained hand grip, and blood pressure and heart rate responses to tilt-up or active standing. The testing must be performed with a tilt table.
• Sudomotor function testing is used to evaluate and document neuropathic disturbances that may be associated with pain. The quantitative sudomotor axon reflex test (QSART), thermoregulatory sweat test (TST), sympathetic skin responses, and silastic sweat imprints are tests of sympathetic cholinergic sudomotor function.

The QSART measures axon reflex-mediated sudomotor responses quantitatively and evaluates post-ganglionic sudomotor function. Recording is usually carried out from the forearm and three lower extremity skin sites to assess the distribution of post-ganglionic deficits.

The TST evaluates the distribution of sweating by a change in color of an indicator powder. This test has a high sensitivity, and its specificity for delineating the site of lesion is greatly enhanced when used in conjunction with QSART.

Sweat imprints are formed by the secretion of active sweat glands into a plastic (silastic) imprint. The test can determine sweat gland density, a histogram of sweat droplet size and sweat volume per area.

Sensory neuropathy

Care of diabetic neuropathy in the feet and elsewhere is very important. Routine Electrodiagnostic testing (EDX) studies are not required simply by the presence of diabetes. Unlike hemoglobin A1c testing or retinal testing, similar periodic EDX testing is not established in well-recognized national protocols for effective diabetic care. The value of incidental EDX testing or tracking in diabetics, including those with loss of sensation, has not been established to improve health outcomes over careful neurologic physical exam testing. EDX testing is appropriate for specific, complex clinical situations where diabetic neuropathy and entrapment or neurologic diagnoses must be further investigated. Examples include investigation of lumbar radiculopathies, carpal entrapment, and diagnostic differentials established by a detailed physical exam and history. While EDX studies have been used in Phase III clinical trials to test drug effectiveness, no current diabetic neuropathy drugs have FDA requirements for EDX monitoring during their use. Medicare’s benefits for routine foot care in diabetics or other neuropathic patients do not require EDX testing before coverage, but are fulfilled by physical exam testing for loss of protective sensation. Refer to National Coverage Determination (NCD) 70.2.1 for diabetic peripheral neuropathy diagnosis with loss of protective sensation listed in the National Coverage section of the policy.

Indications:

Most autonomic disorders are diagnosed clinically, with laboratory and formal diagnostic testing playing an adjunctive or confirmatory role. Testing may also be appropriate to monitor disease progression when there is a change in clinical status, or to evaluate a patient’s response to specific treatment for an autonomic disorder.

Autonomic function testing is covered as reasonable and necessary when used as a diagnostic tool to evaluate symptoms indicative of vasomotor instability, such as hypotension, orthostatic tachycardia, and hyperhidrosis after more common causes have been excluded by other testing, and the ANS testing is directed at establishing a more accurate or definitive diagnosis or contributing to clinically useful and relevant medical decision making for one of the following indications:

1. To diagnose the presence of autonomic neuropathy in a patient with signs or symptoms suggesting a progressive autonomic neuropathy.
2. To evaluate the severity and distribution of a diagnosed progressive autonomic neuropathy.
3. To differentiate the diagnosis between certain complicated variants of syncope from other causes of loss of consciousness.
4. To evaluate inadequate response to beta blockade in vasodepressor syncope.
5. To evaluate distressing symptoms in a patient with a clinical picture suspicious for distal small fiber neuropathy in order to diagnose the condition.
6. To differentiate the cause of postural tachycardia syndrome.
7. To evaluate change in type, distribution or severity of autonomic deficits in patients with autonomic failure.
8. To evaluate the response to treatment in patients with autonomic failure who demonstrate a change in clinical exam.
9. To diagnose axonal neuropathy or suspected autonomic neuropathy in the symptomatic patient.
10. To evaluate and treat patients with recurrent unexplained syncope to demonstrate autonomic failure, after more common causes have been excluded by other standard testing.

Limitations:

Syndromes of autonomic dysfunction for which ANS might add valuable clinical information are relatively rare. Generally, only after excluding more common causes of autonomic signs or symptoms (e.g., hypotension, hyperhidrosis, and orthostatic tachycardia) may formal autonomic testing be indicated to exclude or confirm rarer autonomic disorders. The following indications are considered NOT medically reasonable and necessary and will not be covered:

1. Patient screenings without signs or symptoms of autonomic dysfunction, including patients with diabetes, hepatic or renal disease.
2. Testing for the sole purpose of monitoring disease intensity or treatment efficacy in diabetes, hepatic or renal disease.
3. Testing where the results are not used in clinical decision-making and patient management.
4. Autonomic Disorders is a medical subspecialty defined by competence in: (1) understanding of the health and disease of the autonomic nervous system (ANS); (2) performance and interpretation of clinical and laboratory evaluation of ANS; and (3) diagnosis and care of those who suffer from autonomic dysfunctions. All practitioners performing ANS should meet criteria for eligibility of certification in Autonomic Disorders as recognized by the United Council of Neurologic Subspecialties (UCNS) or such similar organization established by the American Board of Podiatric Medicine. The American Board of Podiatric Medicine shall follow the training requirements and core curriculum requirement established by the UCNS for its Autonomic Disorders Accreditation. Pathways of determining eligibility as outlined by the UCNS including: the applicants must have completed one of two eligibility pathways. The pathways are: 1. Fellowship and 2. Practice Track meeting the criteria as so outlined in one of the pathways substituting only the podiatric medical education requirements certification instead of the AMA/AOA CME requirements.
5. General professional standards with FDA clearance apply to all equipment used in ANS testing.
6. Testing with ANSAR ANX 3.0 or other similar machine is considered investigational or for screening and will not be covered.
7. According to a report from Casellini¹, use of an apparatus for testing electrochemical skin conductance (ESC) that "consist of two sets of large-area stainless steel electrodes for the hands and feet that are connected to a computer for recording and data-management purposes. The electrodes are alternately used as an anode or cathode, and a direct current incremental voltage of less than or equal to 4 V is applied to the anode. Through reverse iontophoresis, the device generates voltage to the cathode and a current (intensity of around 0.2 mA) between the anode and cathode proportional to chloride concentration. At low voltages (less than 10 V), the stratum corneum is electrically insulating, and only sweat-gland ducts are conductive [in theory]." The report continues saying the (ESC) "expressed in microSiemens (µS), is the ratio between the current generated and the constant DC stimulus (less than or equal to 4 V) applied to the electrodes. … During the test, patients were required to place their hands and feet on the electrodes and to stand still for 2–3 min. The device produces ESC results for individual right and left hands and feet. It then calculates an average score between right and left hands and feet. All the ESC results [presented in this study] correspond to the average ESC between right and left sides for both hands and feet. … Neither special subject preparation nor specially trained medical personnel are required."
   
   This apparatus and other similar devices do not meet the same specification for sudomotor testing. Please refer to Billing and Coding Article: Autonomic Function Tests, A54954, for correct coding and billing information related to this particular and similar apparatuses. Most references do not show clear indication of clinical utility for this type of device and were performed primarily as screening tests for diabetic peripheral neuropathy.
   
   As technology continues to improve and the continuing automation takes over more and more of the performance of the test, the need for additional coding will be obvious to describe these new technologies.
8. AFT shall not be used as a test for the diagnosis of a peripheral polyneuropathy of diabetes nor for monitoring of the diabetic patient with peripheral neuropathy.
9. Combined parasympathetic and sympathetic adrenergic function testing with at least 5 minutes of passive tilt does not include beat-to-beat recording and represents a duplication of the services represented by cardiovagal innervation and vasomotor adrenergic innervation. Therefore, Novitas does not consider combined parasympathetic and sympathetic adrenergic function testing to be reasonable and necessary if performed with cardiovagal innervation and vasomotor adrenergic innervation in that this would represent a duplication of services. Combined parasympathetic and sympathetic adrenergic function testing should include beat-to-beat evaluation of response to deep breathing. Providers should refer to the applicable Current Procedural Terminology (CPT) Manual to assist with proper reporting of autonomic function testing.
10. It is expected that parasympathetic and sympathetic heart rate testing would be a component of an initial neurologic assessment. Therefore, it would not be considered a significant, separately identifiable service when performed on the same day as an Evaluation and Management (E/M) service performed to evaluate signs and symptoms of possible autonomic dysfunction.

Equipment for Autonomic Nervous System Studies

Equipment with FDA clearance for heart rate variability measurements in response to paced respirations and exercises that tests only heart rate variability does not meet the full range of testing parameters required for the performance of cardiovagal innervation and vasomotor adrenergic innervation testing, and does not ensure full test requirements, such as blood pressure monitoring and blood oxygen levels; nor do they incorporate proper testing conditions, such as the use of a tilt table. Providers may be asked to supply information on the equipment used to perform autonomic nervous system studies, to ensure that all studies performed meet the requirements of the procedure.

The redetermination process may be utilized for consideration of services performed outside of the reasonable and necessary requirements in this LCD.

N/A

N/A

Refer to the Local Coverage Article: Billing and Coding: Autonomic Function Tests, A54954, for all coding information.

Documentation Requirements

1. All documentation must be maintained in the patient’s medical record and made available to the contractor upon request.
2. Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of service[s]). The documentation must include the legible signature of the physician or non-physician practitioner responsible for and providing the care to the patient.
3. The medical record documentation must support the medical necessity of the services as stated in this policy.

Utilization Guidelines

In accordance with CMS Ruling 95-1 (V), utilization of these services should be consistent with locally acceptable standards of practice.

Appropriate diagnostic testing may be performed once for patients to confirm or exclude specific autonomic disease.

For patients with an identified autonomic disorder, frequency of testing depends on changes in clinical status or response to intervention.

Providers who perform these tests on an unusually high proportion of their patients, or at frequencies exceeding once per patient per year, may be subject to medical review.

Notice: This LCD imposes utilization guideline limitations. Despite Medicare allowing up to these maximums, each patient's condition and response to treatment must medically warrant the number of services reported for payment. Medicare requires the medical necessity for each service reported to be clearly demonstrated in the patient's medical record. Medicare expects that patients will not routinely require the maximum allowable number of services.

Wisconsin Physicians Service Insurance Corporation (WPS), LCD, L35124, Autonomic Function Testing

Noridian Healthcare Solutions, LLC, LCD L33476, Nervous System Studies-Autonomic Function Nerve Conduction and Electromyography

Aetna Clinical Policy Bulletin #0485 Autonomic testing/Sudomotor test 2013

Contractor Medical Directors

Contractor is not responsible for the continued viability of websites listed.

1. Casellini CM, Parson HK, et al. Sudoscan, a Noninvasive tool for detecting Diabetic Small fiber neuropathy and Autonomic dysfunction. Diabetes Technology and Therapeutics. 2013; 15(11):948-953. doi: 10.1089/dia.2013.0129.
2. American Diabetes Association. Standards of Medical Care in Diabetes - 2013. Diabetes Care. 2013; 36(1): S11-S66.
3. The ACCORD Study Group. Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. N Eng J Med. 2011; 364: 818-828.
4. The Action to Control Cardiovascular Risk in Diabetes Study Group. The Effects of Intensive Glucose Lowering in Type II Diabetes. N Eng J Med. 2008; 358: 2545-2559.
5. Ayoub H, Lair V, Griveau S, et al. SUDOSCAN Device for the Early Detection of Diabetes: In Vitro Measurement versus Results of Clinical Tests. American Scientific Publishers. 2011; 9: 2147-2149. doi:10.1166/sl.2011.1756.
6. Bordier L, Dolz M, Monteiro L, et al. Accuracy of a Rapid and Non-Invasive Method for the Assessment of Small Fiber Neuropathy Based on Measurement of Electrochemical Skin Conductances. Frontiers in Endocrinology (Lausanne). 2016; 7: 18. doi: 10.3389/fendo.2016.00018.
7. Calvet JH, Dupin J, Winiecki H, et al. Assessment of small fiber neuropathy through a quick, simple and non invasive method in a German diabetes outpatient clinic. Exp Clin Endocrinol Diabetes. 2013; 121(2): 80-3. doi: 10.1055/s-0032-1323777.
8. Gin H, Baudoin R, Raffaitin CH, et al. Non-invasive and quantitative assessment of sudomotor function for peripheral diabetic neuropathy evaluation. Diabetes Metab. 2011. doi:10.1016/j.diabet.2011.05.003.
9. Hupin D, Pichot V, Celle S, et al. Sudomotor function and obesity-related risk factors in an elderly healthy population: The PROOF-Synapse Study. International Journal of Cardiology. 2015; 186: 247-249. http://dx.doi.org/10.1016/j.ijcard.2015.03.273.
10. Khalfallah K, Ayoub H, Calvet JH, et al. Noninvasive Galvanic Skin Sensor for Early Diagnosis of Sudomotor Dysfunction: Application to Diabetes. IEEE Sensor Journal. 2010: 1-8.
11. Lefaucheur JP, Wahab A, Plante-Bordeneuve V, et al. Diagnosis of small fiber neuropathy: A comparative study of five neurophysiological tests. Neurphysiologie Clinique/Clinical Neurophysiology. 2015. doi:10.1016/j.diabet.2011.05.003.
12. Obici L, Kuks JB, Buades J, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Open access article at www.co-neurology.com. 2016; 129: S27-S35. DOI:10.1097/WCO.0000000000000290.
13. Raisanen A, Eklund J, Calvet JH, et al. Sudomotor Function as a Tool for Cardiorespiratory Fitness Level Evaluation: Comparison with Maximal Exercise Capacity. International Journal of Environmental Research and Public Health. 2014; 11: 5839-5848. doi:10.3390/ijerph110605839.
14. Saad M, Psimaras D, Tafani C, et al. Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy. J Neurooncol. 2016. DOI 10.1007/s11060-015-2049-x.
15. Sahuc P, Chiche L, Dussol B, et al. Sudoscan as a noninvasive tool to assess sudomotor dysfunction in patients with Fabry disease: results from a case-control study. Therapeutics and Clinical Risk Management. 2016: 12: 135-138. Doi: http://dx.doi.org/10.2147/TCRM.S99241.
16. Selvarajah D, Cash T, Davies J, et al. SUDOSCAN: A simple, Rapid, and Objective Method with Potential for Screening for Diabetic Peripheral Neuropathy. 2015. DOI:10.1371/journal.pone.0138224.
17. Smith, GA, Lessard M, Reyna S, et al. The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. Journal of Diabetes and Its Complications. 2014. http://dx.doi.org/10.1016/j.jdiacomp.2014.02.013.
18. Syngle A, Inderjeet V, Krishan P, et al. Disease-modifying anti-rheumatic drugs improve neuropathy in arthritis: DIANA study. Clin Rheumatol. 2014. DOI 10.1007/s10067-014-2716-x.
19. U.S. Food & Drug Administration, Medical Devices. https://www.fda.gov/MedicalDevices/default.htm. Accessed 03/07/2019.
20. Vinik AI, Erbas T, Casellini CM. Diabetic Cardiac Autonomic Neuropathy, Inflammation and Cardiovascular Disease. Journal Diabetes Investig. 2013 Jan; 4(1): 4-18.
21. Vinik AI, Nevoret ML, Casellini CM. The new age of sudomotor function testing: a sensitive and specific biomarker for diagnosis, estimation of severity, monitoring progression, and regression in response to intervention. Frontiers in Endocrinology. 2015. 6(94); 1-12. doi: 10.3389/fendo.2015.00094.
22. Vinik AI, Smith AG, Singleton R, et al. Normative Values for Electrochemical Skin Conductances and Impact of Ethnicity on Quantitative Assessment of Sudomotor Function. Diabetes Technology and Therapeutics. 2016; 18(7): 1-8. Doi: 10.1089/dia.2015.0396.
23. Vinik AI, Ziegler D. Diabetic Cardiovascular Autonomic Neuropathy. Circulation. 2007; 115: 387-397.
24. Yajnik CS, Kantikar V, Pande A, et al. Screening of cardiovascular autonomic neuropathy in patients with diabetes using non-invasive quick and simple assessment of sudomotor function. Diabetes & Metabolism. 2012. http://dx.doi.org/10.1016/j.diabet.2012.09.004.
25. Yajnik CS, Kantikar VV, Pande AJ, et al. Quick and Simple Evaluation of Sudomotor Function for Screening of Diabetic Neuropathy. ISRN Endocrinology. 2012. doi:10.5402/2012/103714.